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Abstract
Background: Chronic kidney disease and end-stage renal disease are major causes of morbidity and mortality that are seen
far more commonly in the aged population. Interestingly, kidney function declines during aging even in the absence of
underlying renal disease. Declining renal function has been associated with age-related cellular damage and dysfunction
with reports of increased levels of apoptosis, necrosis, and inflammation in the aged kidney. Bioactive sphingolipids have
been shown to regulate these same cellular processes, and have also been suggested to play a role in aging and cellular
senescence.
Methodology/Principal Findings: We hypothesized that alterations in kidney sphingolipids play a role in the declining
kidney function that occurs during aging. To begin to address this, the sphingolipid profile was measured in young (3 mo),
middle aged (9 mo) and old (17 mo) C57BL/6 male mice. Interestingly, while modest changes in ceramides and sphingoid
bases were evident in kidneys from older mice, the most dramatic elevations were seen in long-chain hexosylceramides
(HexCer) and lactosylceramides (LacCer), with C14- and C16-lactosylceramides elevated as much as 8 and 12-fold,
respectively. Increases in long-chain LacCers during aging are not exclusive to the kidney, as they also occur in the liver and
brain. Importantly, caloric restriction, previously shown to prevent the declining kidney function seen in aging, inhibits
accumulation of long-chain HexCer/LacCers and prevents the age-associated elevation of enzymes involved in their
synthesis. Additionally, long-chain LacCers are also significantly elevated in human fibroblasts isolated from elderly
individuals.
Conclusion/Significance: This study demonstrates accumulation of the glycosphingolipids HexCer and LacCer in several
different organs in rodents and humans during aging. In addition, data demonstrate that HexCer and LacCer metabolism is
regulated by caloric restriction. Taken together, data suggest that HexCer/LacCers are important mediators of cellular
processes fundamental to mammalian aging.
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Introduction
Many factors are thought to contribute to mammalian aging
including changes in gene expression, mitochondrial dysfunction,
oxidative stress, shortening of telomeres, and accumulation of
advanced glycation end-products. These factors eventually lead to
a decline in organ function and the ability to respond to
physiological and pathophysiological stimuli. In the kidney, there
is an age-associated progressive deterioration in renal function
even in the absence of obvious renal disease [1–3]. Moreover,
many changes occur in the kidney prior to a decline in kidney
function, including increases in pro-inflammatory enzymes and
cytokines [4,5]. Consequently, elucidating the early changes that
lead to a decline in kidney function is critical for the development
of therapeutics aimed at preserving kidney function during aging.
With normal aging, a number of functional and structural
changes occur in the kidney both in humans and in laboratory
animals. These include decreases in renal blood flow and
glomerular filtration rate, changes in tubular function that impair
the ability to concentrate urine, glomerulosclerosis, and tubuloin-
terstitial fibrosis [1–3]. Furthermore, as drug excretion is also
reduced in the aged kidney, the pharmacokinetics and pharma-
codynamics of many drugs used by the elderly are altered, making
them more likely to suffer long-term consequences following acute
kidney injury [1–3]. Ordinarily following acute kidney injury,
damaged tubules are repopulated by proliferation of renal
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diminished in the aged kidney. Thus, the aged kidney has
increased exposure to renal stressors, enhanced susceptibility to
injury, and decreased ability to repair itself following injury. As a
result, the elderly have an increased incidence of renal disease than
younger adults, including chronic kidney disease and end-stage
renal disease.
Caloric restriction (CR), without a reduction in essential
nutrients, is well known to extend the median and maximum
lifespan of mammals and suppresses aging related diseases that
shorten lifespan [6–8]. Importantly, CR also maintains kidney
function during aging [9–11]. CR is thought preserve kidney
function during aging via reduced levels of cellular processes such
as apoptosis, necrosis, and inflammation which are all known to be
elevated during renal aging [11–15]. Thus, understanding precise
mechanisms by which CR protects kidney function during aging is
highly valuable for the future development of novel therapeutics.
Sphingolipids represent a class of bioactive lipids that play
important regulatory roles in apoptosis, necrosis, inflammation,
insulin resistance and diabetes, all of which greatly impact kidney
function and play large roles in kidney disease [16–24]. Ceramide
is a sphingolipid that has been implicated in a variety of cell stress
responses, but is also at the center of sphingolipid metabolism and
is utilized for the synthesis of other bioactive sphingolipids,
including sphingosine-1-phosphate (S1P), sphingosine (Sph), and
the glycosphingolipids hexosylceramide (HexCer) and lactosylcer-
amide (LacCer).
In recent years, evidence has begun to accumulate implicating
ceramides and glycosphingolipids in a number of kidney
pathologies such as acute renal failure, polycystic kidney disease,
Fabry’s kidney disease, renal cancer, and diabetic nephropathy
[25–39]. As sphingolipid levels change during aging in the liver
and brain [40,41], we hypothesized that altered sphingolipid
metabolism in the kidney plays an important role in kidney aging.
To test this hypothesis, sphingolipids were measured in the kidneys
from C57BL/6 male mice at different ages fed both ad libitum (AL)
or a CR diet. Data revealed that long-chain HexCers and LacCers
are significantly elevated during renal aging. These glycosphingo-
lipids are also elevated during aging in the mouse brain and liver
as well as in human fibroblasts obtained from elderly individuals.
Importantly, CR effectively prevented the accumulation of long-
chain HexCers and LacCers in the kidneys of aged mice. Taken
together, these data suggest that HexCers and LacCers are
important mediator of cellular processes fundamental to mamma-
lian aging.
Results
HexCers and LacCers accumulate in the kidneys of aged
mice
Increases in ceramide and sphingosine have been reported in
the liver and brain of aged rats [41,42] and were suggested to be a
hallmark of the aging process. Thus, we hypothesized that similar
changes in sphingolipid metabolism occur during kidney aging. To
test this hypothesis, sphingolipids were quantified from kidney
homogenates of C57BL/6 male mice 3, 9 and 17-months of age
AL from the NIH calorically-restricted rodent colony. Surprising-
ly, results indicated that levels of the sphingoid bases such as
sphingosine (Sph), dihydrosphingosine (dhSph) and sphingosine-1-
phosphate (S1P) did not change significantly with age (Fig. 1a).
Similarly, the levels of sphingomyelin (SM) were not significantly
different between age groups (Fig. 1b). In contrast, dihydrocer-
amide (dhCer) levels (Fig. 1c) were significantly elevated at 9 mo.
but were not significantly elevated in the kidneys of 17 mo. mice.
Similarly, long-chain ceramides also increased with age but not in
a statistically significant manner (Fig. 1d). Likewise, there were no
significant changes in the individual ceramide species (data not
shown).
As glycosphingolipids are highly abundant in the kidney and
play a role in a variety of kidney diseases [28,29,31,39,43–46], we
speculated that there could be age-associated differences in their
levels; accordingly, this was investigated. As depicted in Figs. 1e
and 1f, the most significant changes of all the sphingolipids
measured were that of the simple glycosphingolipids, HexCer and
LacCer. Notably, for HexCers, only the long-chain species were
increased with aging, whereas very long-chain species were
decreased (Fig. 1e). Moreover, within the long-chain species,
C16-HexCer was the only species that accumulated during aging
(Figure S1). In contrast, both long-chain and very long-chain
species of LacCer were significantly elevated during aging (Fig. 1f).
We determined whether specific LacCer species were preferen-
tially elevated during aging. As is evident from Figs. 2a and 2b, all
species of LacCer were significantly elevated with C14 and C16
species being the most significant. These elevations represent
major changes in sphingolipid mass as in the aged kidney C16-
LacCer is the most abundant of all of the classes of sphingolipids
measured, including SM (Fig. 2c).
The kidney, not the blood, is the source of Hexcers and
LacCers during aging
Sphingolipids in the blood are part of the circulating lipoprotein
particles (VLDL, LDL, and HDL), are transported by serum
albumin, and are present in blood cells and platelets [47]. As the
blood is filtered by the kidneys, we reasoned that the blood could
be the source of the renal accumulations of HexCer and LacCer
during aging. To determine if this was the case, the blood
sphingolipid profiles of the various mice age groups were
measured. As can be seen, there were no significant increases in
total ceramides, HexCers or LacCers during aging in the blood
(Fig. 3a) and the individual species of ceramide and HexCer were
also not significantly altered (data not shown). Furthermore, the
major LacCer species present in the kidney, C16-LacCer, did not
change in the blood during aging (Fig. 3b) and although there were
elevations in some species of LacCer in the blood, such as C14,C 22
and C24-LacCer, these were minor changes in mass and represent
species with very low abundance in the kidney (data not shown).
Finally, if blood was the source of the observed LacCer and
HexCer elevations in the aged kidney, then there should be
comparable elevations in these sphingolipids in other highly
perfused organs such as the heart. However, no changes in either
HexCer or LacCer in the heart were observed during aging (data
not shown). Taken together, these results suggest that the
glycosphingolipids were synthesized within the kidney during
aging.
HexCer and LacCer accumulations during aging were not
restricted to the kidney, but occur in the brain and liver
As elevations in sphingosine and ceramide have been docu-
mented in the brain and liver during aging [41,42], we
hypothesized that the HexCer and LacCer accumulations during
aging are not restricted to the kidney. Accordingly, HexCer and
LacCer species in the brain and liver of the mice described above
were analyzed. Results showed that only the long-chain and very
long-chain LacCers increased with age in brain whereas HexCers
were unchanged (Fig 4a and b). In contrast, in the liver, both long-
chain HexCers and long-chain LacCers were elevated during
aging (Fig 4c and d). Overall, these data suggest that the changes
Glycosphingolipids in Kidney Aging
PLoS ONE | www.plosone.org 2 | Issue | e20411 6 Jun 2011 | Volume 6 ein long-chain HexCer and LacCer are observed in many, but not
all (e.g. heart), tissues.
Caloric restriction decreases renal long-chain HexCers
and long-chain LacCers
Increased reactive oxygen species (ROS) and levels of cellular
processes such as inflammation, apoptosis, proliferation, and
senescence occur during aging and have been proposed to shorten
lifespan [48–50]. CR attenuates the levels of these processes during
aging thereby extending lifespan and health span [11,51,52]. As
glycosphingolipids such as HexCer and LacCer regulate these
cellular processes in vitro [53–60], we hypothesized that CR is a
negative regulator of HexCer/LacCer levels. To begin to address
this hypothesis, we examined the impact of CR on renal
sphingolipids in the absence of an additional factor such as aging.
Sphingolipids were analyzed in kidney homogenates from
C57BL/6 male mice obtained from the NIH NIA calorically-
restricted rodent colony either fed AL or a CR diet. Following
analysis, the renal sphingolipid profiles of the CR animals were
compared to age-matched AL control animals. Very long-chain
SM species were increased in mice on the CR diet (Figure S2). As
SM is a highly abundant sphingolipid, this represents a substantial
change in mass. Similar to the increase in very long-chain SM,
mice fed the CR diet exhibited increases in very long-chain Cers
(Figure S2). Interestingly very long-chain HexCers and very long-
chain LacCers were decreased with CR. In addition, CR
significantly reduced long-chain HexCers and LacCers (Figure
S2), with the decrease in long-chain LacCers being the most
significant. Thus, the CR diet profoundly shifted the sphingolipid
profile by decreasing the long-chain Cers, HexCer, and LacCer
and by increasing the very long-chain Cers and very long-chain
SM. These results indicate that CR regulates sphingolipid
metabolism in an opposite pattern to that observed during aging.
Thus, CR is a negative regulator of renal HexCer/LacCer levels.
To further understand the effects of CR on kidney sphingolipids
during aging, data were expressed as a fold-change of the 3 mo.
control mice so that both the variables of diet and age could be
considered together. Sphingoid bases were elevated during aging
in CR animals (Fig. 5a); specifically, dhSph was increased 3-fold in
aged CR mice (Fig. 5a) and Sph was elevated almost 2-fold in the 9
mo. CR mice. S1P was not changed during aging in the CR mice.
Both long-chain and very long-chain dihydroceramide species
were elevated during aging in the CR animals to a much larger
extent than in the AL fed animals (Fig. 5b). These increases in
dihydroceramides in the aged CR mice did not translate to
increases in long-chain Cers, as they were not elevated during
aging in animals on a CR diet (Fig. 5c). Long-chain SM was
elevated during aging in the CR animals, which represents a
substantial change in mass as the long-chain SM are highly
abundant in the kidney (Fig. 5d). Importantly, the elevations in
long-chain HexCer and LacCer observed in AL animals during
aging are not found in CR mice. Restriction of calories was
sufficient to prevent accumulations in the long-chain HexCer and
long-chain LacCer species during aging, but not the very long-
Figure 1. Renal sphingolipid levels in the kidneys of young, middle-aged, and older mice. The sphingolipid profile of kidney
homogenates obtained from young (3 mo), middle-aged (9 mo) and older (17 mo) C57BL/6 male mice from the NIH calorically-restricted rodent
colony. Sphingolipids were quantified by mass spectrometry and normalized to total protein. (a) sphingoid bases including sphingosine (Sph),
dihydrosphingosine (dhSph) and sphingosine-1-phosphate (S1P), (b) Sphingomeylin, (c) dihydroceramide, (d) ceramide, (e) hexosylceramide, and (f)
lactosylceramide where LC refers to the total long-chain species (C14–C20) species and VLC to the total very long-chain species (C22–C26). Data
represent mean 6 SEM; n=6. * p,0.05, **p,0.01, and ***p,0.001, based on nonparametric one-way ANOVA; * indicates significance compared to 3
mo. mice, # indicates significance compared to the 9 mo. mice.
doi:10.1371/journal.pone.0020411.g001
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chain glycosphingolipids are important mediators of biological
processes fundamental to aging.
Caloric restriction prevents the age-associated increase in
neutral sphingomyelinase and long-chain ceramide
synthase
The above data suggest that CR regulates enzymes responsible
for the accumulation of HexCer and LacCer. During aging there
is enhanced production of ceramides within the kidney, which is
prevented by CR (Fig. 5). Ceramides are required substrates for
the production of glycosphingolipids. Indeed, enzymes involved in
ceramide synthesis are altered during aging and elevated liver
neutral sphingomyelinase activity during aging is attenuated by
CR [61,62]. Thus, we hypothesized that HexCer and LacCer
accumulations during aging occur as a result of enhanced substrate
availability. To begin to address this hypothesis, we measured the
activities of enzymes responsible for synthesis of ceramide in
homogenates prepared from the kidneys of 3 and 17 month old
mice fed AL as well as 17 month old mice on a CR diet. Both
neutral sphingomyelinase (nSMase) and long-chain ceramide
synthase (CerS) activities were elevated in the kidney during aging
(Fig. 6a and b). Importantly, CR attenuated the age-associated
increase in both nSMase and long-chain CerS activity (Figs. 6a
and 6b). These data are consistent with the lipid data (Fig. 5) and
suggest that CR prevents accumulation of HexCer and LacCer
Figure 2. Abundance and levels of individual lactosylceramide species during aging in the kidney. Sphingolipids were measured in 3
mo. and 17 mo. old AL mice and the individual (a) long-chain (LC, C14–C20), (b) very-long chain (VLC, C22–C26) lactosylceramide species; and c)
sphingolipids with C16 fatty acyl chains are shown. Data represent mean 6 SEM; n=6. ***p,0.001 according to a nonparametric one-way ANOVA.
doi:10.1371/journal.pone.0020411.g002
Figure 3. Hexosylceramides (HexCer) and lactosylceramides (LacCer) were not elevated in the blood during aging. Sphingolipids were
measured in the 100 mL of whole blood obtained from 3, 9 and 17 mo. AL mice. Data are expressed as a fold-change over the 3 mo. animals for (a)
total ceramides (Cer), HexCer and LacCer as well as (b) C16-LacCer. Data represent mean 6 SEM; n=6.
doi:10.1371/journal.pone.0020411.g003
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increase in nSMase and long-chain CerS activities.
Long-chain HexCer and LacCer accumulate during aging
in humans
The above data implicate glycosphingolipids as important
factors in mouse aging, particularly in the kidney, brain and liver.
Thus, it became important to determine whether HexCer and
LacCer accumulations during aging were also relevant to humans.
For this, commercially available fibroblasts isolated from humans
at 24, 48, and 84 years of age and grown in culture were utilized.
As can be seen, long-chain HexCers were significantly higher in
the fibroblasts of the 84 year old. This was also true for both the
long-chain and very long-chain LacCers species (Fig. 7a and 7b).
Notably, there were no statistically significant changes in any other
sphingolipid species measured (data not shown). Taken together,
this suggests that elevated levels of long-chain HexCer and
LacCers are relevant biomarkers of aging in humans as well as in
murine models.
Discussion
In this study, we report elevations in the levels of the
glycosphingolipids HexCers and LacCer during aging in the
kidney, liver and brain of C57BL/6 male mice fed ad libitum.I n
addition, elevations in glycosphingolipids were also observed in
human fibroblasts isolated from elderly individuals compared to
younger individuals. Importantly, CR inhibited glycosphingolipid
accumulation during aging in the kidneys. To our knowledge, this
is the first study to describe alterations in kidney sphingolipids
during aging. More importantly, this is the first report describing
regulation of sphingolipid metabolism by an intervention known to
attenuate aging. As CR is known to extend median and maximum
lifespan of mammals, these data suggest that glycosphingolipid
mediate declining renal function during aging.
Given the findings of this study and published work on renal
glycosphingolipids, the results suggest the involvement of glyco-
sphingolipids in the deterioration of renal function during aging.
Glycosphingolipids such as HexCer and LacCer are highly
abundant in the kidney and considerable evidence has implicated
them in a variety of kidney pathologies [53–59]. For example,
glycosphingolipid accumulation has been reported in models of
polycystic kidney disease whereas preventing their accumulation
with inhibitors of glucosylceramide synthase was shown to prevent
the onset of this disease [29]. Furthermore, accumulation of
glycosphingolipids also occurs in Fabry’s kidney disease, glomer-
ular nephritis, and in renal cancer [28,35,39,43,45,63–65]. The
current work demonstrates increased glycosphingolipid levels in
the kidney during aging, thereby providing a possible and
plausible explanation for the increased susceptibility and incidence
of kidney disease seen in the elderly. Consistent with this theory,
CR is well known to slow the aging process in a wide range of
species including mammals, has been shown to maintain kidney
function throughout aging and, here, was found to prevent the
accumulation of HexCers and LacCers. Thus, therapeutics aimed
at the regulation of glycosphingolipids may be useful for the
maintenance of kidney function during aging, as well as being able
to treat a variety of kidney diseases.
In addition to accumulation of glycosphingolipids, our data also
show increased ceramide levels in the aged kidneys that is also
prevented by CR, consistent with a profound alteration of
sphingolipid metabolism during aging. Notably, these data are
similar to previous reports demonstrating elevations in sphingosine
and ceramide levels in aging livers of rats [41,66]. In the brain,
C24-galactosylceramide has been reported to accumulate in the
cerebral cortex during aging [40]. Unlike Cutler et al., 2004, we
do not detect statistically significant changes in C24-hexosylcer-
amide in the aged brain, but rather only an accumulation of
lactosylceramides. However, our results may differ than those
previously reported [40] for several reasons, including measure-
ment of hexosylceramides rather than specifically galactosylcer-
amides, utilization of a different methods of sacrifice, use of
different aged mice. Regardless, data presented here extend on the
results of earlier studies by demonstrating elevated levels of
LacCers in both liver and brain during aging.
The involvement of sphingolipids in aging is perhaps not
surprising; indeed, there is considerable evidence linking sphingo-
lipid genes with life span. For example, the longevity assurance
gene (LAG1) in yeast was one of the first genes implicated in yeast
aging [67] whose deletion was found to extend lifespan and was
subsequently discovered to encode a ceramide synthase [68,69], a
key enzyme in the ceramide synthetic pathway. Furthermore,
sphingolipid metabolism has been shown to play an important role
in determining Drosophila lifespan [70,71]. Breakdown of ceramide
into sphingosine and fatty acids is catalyzed by the enzyme
ceramidase. It was recently reported that the Drosophila alkaline
ceramidase plays an important role in Drosophila development
and longevity as mutation of alkaline ceramidase significantly
increases the mean and maximum lifespan [71]. Finally, the
ceramide transfer protein (CERT) regulates cellular ceramide
levels by transporting ceramide from the ER to the Golgi where it
is used specifically for SM synthesis. Notably, CERT mutant flies
Figure 4. HexCers and LacCers are elevated in the brain and
liver during aging. The sphingolipid profile was measured in brain (a
and b) and liver (c and d) of 3, 9 and 17 mo. AL mice. Data were
normalized to total protein and expressed as a fold-change over the 3
month mice. Data represent the mean 6 SEM; n=6. (a–d) LC refers to
the total long-chain species (C14–C20) species and VLC to the total very
long-chain species (C22–C26). * p,0.05, **p,0.01, and ***p,0.001
according to nonparametric one-way ANOVA. For a–d * indicates
significance compared to the 3 mo. and # indicates significance
compared to the 9 mo.
doi:10.1371/journal.pone.0020411.g004
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lifespan [70]. Taken together, these studies in model organisms
such as yeast and Drosophila firmly establish that sphingolipids play
important roles in determining lifespan and, by extension, are
important regulators of the aging process.
Although a considerable increase in HexCers and LacCers was
observed in aged kidneys in the present study, the mechanism by
which this occurs is unclear. Given that ceramide levels were also
increased and ceramide is a precursor of the complex sphingolip-
ids, this implies enhanced synthesis. Consistent with this theory,
neutral sphingomyelinase (nSMase) and long-chain ceramide
synthase (CerS) activities are elevated in the kidney during aging,
which are prevented by caloric restriction (Fig. 6a and b). Age-
associated changes in the activity of a number of sphingolipid
Figure 5. Impact of caloric restriction on renal LC-HexCers and LC-LacCers during aging. The sphingolipid profile was measured in the
kidneys of 3, 9, or 17 mo. old mice fed either AL or on CR diet. Data were normalized to total protein, totals from the LC (C14–C20) and VLC (C22–C26)
species calculated, and expressed as the fold-change of the 3 mo. mice. (A) sphingoid bases dihydrosphingosine (dhSph), sphingosine (Sph), and
sphingosine-1-phosphate (S1P); (b) dihydroceramides; (c) ceramides; (d) sphingomyelins; (e) hexosylceramides; and (f) lactosylceramides. Data
represent mean 6 SEM; n=5–6. Statistical analysis was performed using a rank-transformation followed by a two-way ANOVA with a Bonferroni post-
test. * indicates significant difference compared to the 3 mo. AL mice, whereas # indicates a significant difference compared to the age-matched AL
value. * p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0020411.g005
Figure 6. Neutral sphingomyelinase and long-chain ceramide
synthase activities in kidney homogenates of young and old
mice fed ad libitum and calorically restricted. Neutral sphingo-
myelinase (a) and long-chain ceramide synthase (b) activities were
measured in kidney homogenates from the indicated aged mice (in
months) fed ad libitum (AL) or on a calorically restricted (CR) regime as
described in the materials and methods. Data represent mean 6 SEM;
n=5–6. * p,0.05 as compared to the 3 AL control mice according to
nonparametric one-way ANOVA.
doi:10.1371/journal.pone.0020411.g006
Figure 7. Long-chain HexCer and LacCer levels in aged human
tissues. HexCer (a) and LacCer (b) were measured in commercially
available (Coriel) human fibroblast cells isolated from 24, 48 and 84
year-old humans and grown in culture as described in the materials and
methods. LC refers to the total long-chain species (C14–C20) species and
VLC to the total very long-chain species (C22–C26). Data represent the
mean 6 SEM; n=3. * p,0.05, **p,0.01, and ***p,0.001 according to
nonparametric one-way ANOVA.
doi:10.1371/journal.pone.0020411.g007
Glycosphingolipids in Kidney Aging
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nSMase2, ceramidase, and SM synthase [62]. Furthermore,
during aging, there is elevated oxidative stress and free radical
generation within the kidney that is reduced with CR. Important-
ly, nSMase2 is regulated by reactive oxygen species (ROS) [66,72–
75]. ROS-mediated activation of nSMase2 was implicated in the
increased ceramide levels observed in the liver of aged rats [61,66]
and this was also attenuated by CR [61]. Moreover, glycosphin-
golipid synthesis is reported to be dependent on nSMase activity
[60,76–78]. Finally, elevated ROS levels have also been reported
in many kidney diseases where glycosphingolipids are also known
to play a role [79–83]. Taken together, this suggests that
glycosphingolipid levels increase during aging owing to increased
production of substrates, and this is prevented by CR. Certainly,
our lipid data and our enzyme activity measurements are
consistent with this possibility (Figs. 5 and 6). However, we cannot
rule out the possibility that enhanced breakdown of complex
glycosphingolipids could also contribute to accumulations in
HexCer/LacCer. Alternatively, enhanced production of HexCer
and LacCer could also lead to elevated levels of complex
glycosphingolipids in the aged kidney, including globosides and
gangliosides that are highly abundant in the kidney and play a role
in numerous kidney diseases [84]. Thus, studies are underway to
both evaluate the contribution of the different sphingolipid
enzymes to the accumulation of HexCer and LacCer during
aging as well as determine if altered metabolism of complex
glycosphingolipids plays a role in renal aging.
Although the results raise the possibility that glycosphingolipids
may play important roles in renal aging, the mechanism(s) by
which glycosphingolipid accumulation adversely affects the kidney
are unclear. Both HexCer and LacCer are well established
regulators of biological processes such as cell proliferation,
apoptosis and inflammation [53–59]. Consequently, alterations
in any (or all) of these processes may contribute to age-related
pathology. However, to begin to address the mechanisms of
glycosphingolipid action more fully, it will first be important to
understand the location of accumulated glycosphingolipids within
the kidney. While the current data confirm that increased HexCer
and LacCer are synthesized within the kidney rather than
delivered by the blood, there are many different cell types within
the kidney that could act as the source. Indeed, identifying the
location within the kidney in which HexCer and LacCer
accumulate during aging will offer some insight into their relevant
pathologies.
In summary, this study demonstrates accumulation of the
glycosphingolipids HexCer and LacCer during kidney aging that is
prevented by CR. This implicates the glycosphingolipids as
important mediators of kidney aging and, indeed they regulate
processes fundamental to aging. As renal disease represents a
significant cause of morbidity and mortality in the elderly
population, these data open a new avenue of potential therapeutic
intervention. Indeed, as inhibitors of glycosphingolipid synthesis
are well tolerated in rodents and are currently being utilized for
treatment of Gaucher disease patients, the potential for translation
to humans is considerable.
Materials and Methods
Materials
BCA Protein Determination Kit was from Pierce (Rockford,
IL).Phosphatase inhibitor cocktails were from Sigma (St. Louis,
MO) and protease inhibitor tablets were from Roche Diagnostics
(Indianapolis, IN). Choline-methyl-
14C]sphingomyelin was synthe-
sized by and obtained from MUSC Lipidomics Core Facility.
C17-sphingosine, porcine brain sphingomyelin, and C16-fatty acyl
CoA were obtained from Avanti Polar Lipids (Alabaster, AL).
Cell Culture
Human dermal fibroblasts from 24- (AG11732), 48- (AG11793),
and 84-year old (AG11725) females were obtained from the
Coriell Cell Repository. Cells were maintained in high-glucose
DMEM supplemented with 10% (v/v) fetal bovine serum without
antibiotics. Cells were used from passage 10–16. For sphingolipid
measurements, adherent cells were washed twice with cold PBS
and lysed in buffer containing 1% Triton X-100, 50 mM Tris (pH
7.4), 0.15 M NaCl, 1.0 mM EDTA, supplemented with protease
and phosphatase inhibitors. Cellular homogenates (0.1–1.0 mg)
were frozen at 280uC until submission for sphingolipid analysis.
Animals and Diets
Male C57BL/6 mice were purchased from the National
Institute of Health National Institute of Aging (NIA) aged rodent
colonies (Bethesda, MD, USA). Animals from 3 different ages were
used in this study: 3, 9 and 17-month old. All mice were
maintained on a 12-hour light/12-hour dark cycle and provided
food and water AL for 3 months. At 14 weeks of age, they were
divided into 2 groups, singly housed, and either kept on the AL
diet or initiated on a CR diet. For each group at least 5 total
animals were utilized. The final CR diet consisted of a 40%
reduction in total calories without a reduction in essential nutrients
and was initiated in a stepwise fashion. All animal procedures were
approved by the Medical University of South Carolina (MUSC)
Institutional Animal Care and Use Committee (protocol approval
#2760) and followed the guidelines of the American Veterinary
Medical Association.
Kidney, Plasma, Liver and Brain Collection and
Homogenization
Seven to ten days after their arrival, animals were sacrificed and
plasma collected. The kidney, liver and brain were rapidly
removed and weighed. The organs were snap frozen in liquid
nitrogen and stored at 280C. Tissue samples were excised from
each frozen organ and then homogenized, using a Tissue-Tearor
(Biospec Products, Inc), in 20 mM Tris-HCl (pH 7.4) containing
protease inhibitors.
Quantification of sphingolipids
1 mg of protein from tissue or 0.1–1.0 mg protein from cellular
homogenate was utilized for quantification of sphingolipids species
performed by the Lipidomics Shared Resource Facility at the
Medical University of South Carolina (MUSC) HPLC/MS as
previously described [85]. Data was normalized to total protein as
well as total lipid phosphate.
Neutral sphingomyelinase activity
Neutral sphingomyelinase (nSMase) activity was assessed in vitro
using [choline-methyl-
14C] sphingomyelin as described previously
[86]. Briefly and with modifications, kidney homogenates were
diluted in lysis buffer (0.2% Triton X-100, 50 mM Tris-HCl-pH
7.4, 1.0 mM EDTA with phosphatase and protease inhibitors).
100 mL of reaction mixture was added containing 100 mM, 1610
5
cpm of [choline-methyl-
14C] sphingomyelin (synthesized by and
obtained from the MUSC Lipidiomics Core Facility) presented in
micelles containing 0.2% Triton X-100 in 50 mM Tris-HCl
(pH 7.4) and 0.1 mM ZnCl2. After 30 min at 37uC, the reaction
was terminated by adding 1.5 mL of chloroform/methanol (2:1,
v/v) followed by addition of 0.4 mL of water. Samples were then
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to separate phases. Aliquots (800 mL) of the upper (aqueous) phase
were used for liquid scintillation counting. The activity was
expressed as pmol/mg protein/h. 25 mg of kidney homogenate
was used for nSMase activity measurements, as this was
determined to be within the linear range for enzyme activity.
Long-chain ceramide synthase activity measurements
Ceramide synthase activity was measured as previously
described [87,88]. Briefly and with modifications, 50 mg kidney
homogenate was utilized as this was determined to be within the
linear range for enzyme activity. A reaction mix (100 mL final
volume) containing 15 mMC 17 sphingosine and 50 mMC 16 fatty
acyl-CoA in 25 mM potassium phosphate buffer (pH 7.4) was pre-
warmed at 37uC for 5 min. The enzyme reaction was initiated via
addition of 50 mg kidney homogenate and after 15 min at 37uC
was terminated via the addition of 2 mL of extraction solvent
containing ethyl acetate/2-propanol/water (60/30/10 v/v/v)
supplemented with internal standard for EI/LC/MS analysis.
Lipids were extracted twice, dried under a stream of nitrogen, and
resuspended into 150 mL 1 mM NH4COOH in 0.2% HCOOH
in methanol and analyzed by EI/LC/MS by the MUSC
Lipidomics Core Facility.
Statistical Analysis
For statistical analysis an either one-way or two-way ANOVA
was performed with a Bonferroni post-test. * indicates a
statistically significant difference between the indicated value and
the 3 mo. controls, # indicates a statistically significant difference
between 9 mo. and 17 mo. animals. * p,0.05, **p,0.01,
***p,0.001.
Supporting Information
Figure S1 Levels of individual hexosylceramide species
during aging in the kidney. Hexosylceramides were measured
in 3 mo. and 17 mo. old AL mice and the individual (a) long-chain
(LC, C14–C20) and (b) very-long chain (VLC, C22–C26) species
shown. Data represent mean 6 SEM; n=6. ***p,0.001
according to a nonparametric one-way ANOVA.
(PDF)
Figure S2 Caloric restriction regulation of renal sphin-
golipid levels. The sphingolipid profile was measured in 9 and
17 month old CR mice and age-matched littermate AL mice all
obtained from the NIH NIA calorically-restricted mouse colony.
Lipid data were normalized to total protein and the mean value
calculated for each group. Data are expressed as a Log2 of the
ratio of the CR mean to the age-matched littermate AL mean for
(a) sphingomyelin, (b) ceramide, (c) hexosylceramide, and (d)
lactosylceramide. LC refers to long-chain species (C14–C20) species
and VLC to the very long-chain species (C22–C26). n=5–6.
(PDF)
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